Printer Friendly

Teva receives additional regulatory exclusivity for TREANDA from US FDA.

M2 EQUITYBITES-November 28, 2013-Teva receives additional regulatory exclusivity for TREANDA from US FDA(C)2013 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Wednesday the grant of orphan drug exclusivity for TREANDA by the US Food and Drug Administration (FDA) through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Orphan status is granted to therapies intended to treat diseases or conditions that affect fewer than 200,000 patients in the US.

With the previously granted six months of paediatric exclusivity for TREANDA, regulatory exclusivity for this indication is now extended through April 2016.

TREANDA is also indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL). TREANDA has orphan drug exclusivity for this indication through March 2015. With the previously granted six months of paediatric exclusivity for TREANDA, regulatory exclusivity for this indication lasts until 20 September 2015.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 28, 2013
Words:174
Previous Article:Forestar Group closes its USD144.8m 6% tangible equity units offering.
Next Article:US OCZ receives takeover offer from Toshiba in bankruptcy auction.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |